Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 1277Carcinoma, Non-Small-Cell Lung 926Prostatic Neoplasms 729Neoplasms 632Multiple Myeloma 553Lymphoma 539Colorectal Neoplasms 529Lung Neoplasms 515Leukemia 497Leukemia, Myeloid, Acute 472Neoplasm Metastasis 470Melanoma 425Lymphoma, Non-Hodgkin 417Ovarian Neoplasms 416Leukemia, Lymphocytic, Chronic, B-Cell 386Pancreatic Neoplasms 373Recurrence 335Precursor Cell Lymphoblastic Leukemia-Lymphoma 327Head and Neck Neoplasms 306Lymphoma, Large B-Cell, Diffuse 294Glioblastoma 294Myelodysplastic Syndromes 287Brain Neoplasms 287Lymphoma, Follicular 286Stomach Neoplasms 280Carcinoma, Renal Cell 268Hodgkin Disease 261Carcinoma, Hepatocellular 261Rectal Neoplasms 256Sarcoma 250

Interventions

anlotinib 1NVP-BKM120 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × Advanced Endometrial Cancer × Clear all
NCT04574284 2025-05-28

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
170 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT01289041 2019-05-30

BKM120 as Second-line Therapy for Advanced Endometrial Cancer

Novartis

Phase 2 Completed
70 enrolled 8 charts
Gynecologic

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡